| Literature DB >> 28440608 |
Hamide Mehravaran1, Manoochehr Makvandi, Alireza Samarbaf Zade, Niloofar Neisi, Hadis Kiani, Hashem Radmehr, Toran Shahani, Seyedeh Zeinab Hoseini, Nastaran Ranjbari, Rahil Nahid Samiei.
Abstract
Background and Objective: The human cytomegalovirus (HCMV) can persist lifelong as a latent infection and may result in a series of disorders. Associations with both Hodgkin’s disease and non-Hodgkin´s lymphomas have been reported. Expression of the unique long (UL)138 gene of HCMV is linked with the viral latency phase while that of the immediate-early (IE)1 gene is typical of the viral replication phase in patients. This study conducted to determine the prevalence of CMV latent infection in histological tissue samples from patients with Hodgkin’s and Non-Hodgkin´s lymphomas. Material andEntities:
Keywords: Human Cytomegalovirus; nested PCR; Hodgkin disease; Non-Hodgkin lymphoma
Year: 2017 PMID: 28440608 PMCID: PMC5464470 DOI: 10.22034/APJCP.2017.18.3.593
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Primers and Amplification Conditions Used for Detection of UL138 and IE1
| Name | Primers (5 to 3) | PCR conditions | ||||
|---|---|---|---|---|---|---|
| Forward | Reverse | Annealing Temprature C | Annealing | Cycles n | Size bp | |
| UI138 | ATGGACGATCTGCCGCTGAA1 | TCACGTGTATTCTTGATGAT1 | 52 | 60 sec | 35 | 510 |
| IE1 | GCTTACCACTGGCACGACACCT | TACTCCCCGTACAGCTCGCAAC | 69 | 60 sec | 40 | 89 |
| AGCCTTCCCTAAGACCACCAAT | CATAGCAGCACAGCACCCGACA | 57 | 60 sec | 40 | 260 | |
Profile of Patients with Hodgkin and Non-Hodgkin
| Category | Male | Female | Total |
|---|---|---|---|
| Hodgkin Lymphoma n = 25 | |||
| Mixed Cellularity (MC) | 4 (16%) | 8 (32%) | 12 (48%) |
| Lymphocyte Predominant (LP) | 3 (12%) | 2 (8%) | 5 (20%) |
| Nodular Sclerosis (NS) | 4 (16%) | 4 (16%) | 8 (32%) |
| Non-Hodgkin Lymphoma n= 25 | |||
| Diffuse Large Cell Type | 4 (16%) | 10 (40%) | 14 (56%) |
| Small Lymphocytic Lymphoma | 1 (4%) | 1 (4%) | |
| High Grade Immunoblastic Lymphoma | 1 (4%) | 1 (4%) | |
| Mixed Small and Large | 2 (8%) | 2 (8%) | |
| Malignant T Cell | 2 (8%) | 2 (8%) | 4 (16%) |
| Malignant B Cell | 1 (4%) | 1 (4%) | 2 (8%) |
| Diffuse Mixed Large Cell | 1 (4%) | 1 (4%) |
Detection of UL138, I E1 in Subsets of Hodgkin and Non-Hodgkins Lymphoma
| Characteristic | Hodgkin (n=25) | Non-Hodgkin (n=25) | |||||
|---|---|---|---|---|---|---|---|
| UL138 | IE1 | Total | UL138 | IE1 | Total | ||
| Gender | Female | - | - | 14 | 3(12%),2DLBL*1MTC* | 1(4%)DLBL* | 11 |
| Male | 1(4%) | - | 11 | 2(8%), 1DLBL*1 MTC* | - | 14 | |
| Age group | <16 | - | - | 4 | - | - | 7 |
| >16 | 1(4%) | - | 21 | 5(20%) | 1(4%) | 18 | |
NS*, Nodular Sclerosis; DLBL*, Diffuse Large B-cell Lymphoma; MTC*
Figure 1Results of Nested PCR Amplification of UL138 (Positive Band 89 bp) Lane 1:50-bp Size Marker, Lane 2 :Positive Control, Lane 3:Negative Control. Lane 4-8:Non-Hodgkin Samples Positive for UL138.